1,3,7-Trimethyluric Acid

1,3,7-Trimethyluric Acid (CAS No.: 5415-44-1) is a naturally occurring metabolite of caffeine generated primarily through cytochrome P450-mediated oxidation, particularly via CYP3A4, and is classified as a methylated uric acid derivative widely utilized in pharmacokinetic and metabolic research. As a downstream product of caffeine biotransformation, it serves as a sensitive endogenous probe for assessing CYP3A activity, where the metabolic ratio of 1,3,7-trimethyluric acid to caffeine is commonly employed as a noninvasive biomarker to evaluate interindividual variability in drug metabolism and enzyme function. Functionally, this compound has been associated with modulation of oxidative processes, demonstrating the ability to scavenge reactive oxygen species such as hydroxyl radicals and to inhibit lipid peroxidation in cell-free and membrane-based systems at micromolar concentrations, suggesting a role in redox-related pathways. In biomedical research, it is broadly applied in studies of drug metabolism, enzyme phenotyping, and pharmacokinetic modeling, as well as in investigations of oxidative stress mechanisms. Experimental use typically involves in vitro assays, human biomonitoring studies, or preclinical models, with concentrations selected according to specific study designs to probe CYP3A-dependent metabolic dynamics and associated biological responses.